Vanda wants to gain an advantage in the field of neurological medicine. Vanda Pharmaceuticals is a pharmaceutical company that is developing several drugs for disorders of the central nervous system. The company's lead drug candidate, schizophrenia treatment Fanapt, received FDA approval in 2009. Other drug candidates are treatments for sleep disorders, including insomnia and sleep apnea, and depression. Vanda typically licenses development and commercialization rights for its compounds from companies including Bristol-Myers Squibb and Novartis.